Determination of Regulatory Review Period for Purposes of Patent Extension; MERREMRegister I.V.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 96E-0388]

Determination of Regulatory Review Period for Purposes of Patent

Extension; MERREM I.V.

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) has determined the

regulatory review period for MERREM I.V. and is publishing

this notice of that determination as required by law. FDA has made the

determination because of the submission of an application to the

Commissioner of Patents and Trademarks, Department of Commerce, for the

extension of a patent which claims that human drug product.

ADDRESSES: Written comments and petitions should be directed to the

Dockets Management Branch (HFA-305), Food and Drug Administration,

12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health

Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301-443-1382.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term

Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug

and Patent Term Restoration Act (Pub. L. 100-670) generally provide

that a patent may be extended for a period of up to 5 years so long as

the patented item (human drug product, animal drug product, medical

device, food additive, or color additive) was subject to regulatory

review by FDA before the item was marketed. Under these acts, a

product's regulatory review period forms the basis for determining the

amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: A

testing phase and an approval phase. For human drug products, the

testing phase begins when the exemption to permit the clinical

investigations of the drug becomes effective and runs until the

approval phase begins. The approval phase starts with the initial

submission of an application to market the human drug product and

continues until FDA grants permission to market the drug product.

Although only a portion of a regulatory review period may count toward

the actual amount of extension that the Commissioner of Patents and

Trademarks may award (for example, half the testing phase must be

subtracted as well as any time that may have occurred before the patent

was issued), FDA's determination of the length of a regulatory review

period for a human drug product will include all of the testing phase

and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product

MERREM I.V. (meropenem). MERREM I.V. is indicated

as single agent therapy for the treatment of the following infections

[[Page 6262]]

when caused by susceptible strains of the following designated

microorgranisms: Intra-abdominal Infections: Complicated appendicitis

and peritonitis caused by viridans group streptococci, Escherichia

coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides

fragilis, B. thetaiotaomicron, and Peptostreptococcus species.

Bacterial Meningitis (pediatric patients gr-thn-eq 3 months only):

Bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus

influenzae (-lactamase and non--lactamase-producing

strains), and Neisseria meningitidis. Subsequent to this approval, the

Patent and Trademark Office received a patent term restoration

application for MERREM I.V. (U.S. Patent No. 4,943,569) from

Sumitomo Pharmaceutical Co., Ltd., and the Patent and Trademark Office

requested FDA's assistance in determining this patent's eligibility for

patent term restoration. In a letter dated November 4, 1996, FDA

advised the Patent and Trademark Office that this human drug product

had undergone a regulatory review period and that the approval of

MERREM I.V. represented the first permitted commercial

marketing or use of the product. Shortly thereafter, the Patent and

Trademark Office requested that FDA determine the product's regulatory

review period.

FDA has determined that the applicable regulatory review period for

MERREM I.V. is 2,608 days. Of this time, 1,640 days occurred

during the testing phase of the regulatory review period, while 968

days occurred during the approval phase. These periods of time were

derived from the following dates:

1. The date an exemption under section 505(i) of the Federal Food,

Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective: May 3,

1989. FDA has verified the applicant's claim that the date that the

investigational new drug application became effective was on May 3,

1989.

2. The date the application was initially submitted with respect to

the human drug product under section 507 of the Federal Food, Drug, and

Cosmetic Act (21 U.S.C. 357): October 28, 1993. FDA has verified the

applicant's claim that the new drug application (NDA) for

MERREM I.V. (NDA 50-706) was initially submitted on October

28, 1993.

3. The date the application was approved: June 21, 1996. FDA has

verified the applicant's claim that NDA 20-506 was approved on June 21,

1996.

This determination of the regulatory review period establishes the

maximum potential length of a patent extension. However, the U.S.

Patent and Trademark Office applies several statutory limitations in

its calculations of the actual period for patent extension. In its

application for patent extension, this applicant seeks 1,063 days of

patent term extension.

Anyone with knowledge that any of the dates as published is

incorrect may, on or before April 14, 1997, submit to the Dockets

Management Branch (address above) written comments and ask for a

redetermination. Furthermore, any interested person may petition FDA,

on or before August 11, 1997, for a determination regarding whether the

applicant for extension acted with due diligence during the regulatory

review period. To meet its burden, the petition must contain sufficient

facts to merit an FDA investigation. (See H. Rept. 857, part 1, 98th

Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the format

specified in 21 CFR 10.30.

Comments and petitions should be submitted to the Dockets

Management Branch (address above) in three copies (except that

individuals may submit single copies) and identified with the docket

number found in brackets in the heading of this document. Comments and

petitions may be seen in the Dockets Management Branch between 9 a.m.

and 4 p.m., Monday through Friday.

Dated: January 31, 1997.

Stuart L. Nightingale,

Associate Commissioner for Health Affairs.

[FR Doc. 97-3313 Filed 2-10-97; 8:45 am]

BILLING CODE 4160-01-F